Cargando…
Treatment targets in SLE: remission and low disease activity state
Treat-to-target strategies have changed the approach to management of many chronic conditions, with improvements in patient outcomes. The key to success of treat to target is the availability of validated treatment endpoints, which have been difficult to derive for SLE, a condition notorious for its...
Autores principales: | Golder, Vera, Tsang-A-Sjoe, Michel W P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719036/ https://www.ncbi.nlm.nih.gov/pubmed/33280016 http://dx.doi.org/10.1093/rheumatology/keaa420 |
Ejemplares similares
-
New developments in systemic lupus erythematosus
por: Tsang-A-Sjoe, Michel W. P., et al.
Publicado: (2021) -
Improving access to SLE therapies in low and middle-income countries
por: Mendoza-Pinto, Claudia, et al.
Publicado: (2023) -
The global epidemiology of SLE: narrowing the knowledge gaps
por: Barber, Megan R W, et al.
Publicado: (2023) -
New biomarkers in SLE: from bench to bedside
por: Capecchi, Riccardo, et al.
Publicado: (2020) -
Genetics of SLE: does this explain susceptibility and severity across racial groups?
por: Demkova, Karin, et al.
Publicado: (2022)